Mingyuan Wang

Mingyuan Wang

Auto-generated profile, based on publicly available information

Mingyuan Wang

Department of Transfusion Research Laboratory Suzhou Blood Center Suzhou Jiangsu China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2024 in Scandinavian Journal of Rheumatology
Verified
Journal Article
Closed access
TLT Liu
T Liu
MWM Wang
M Wang
LLL Li
L Li
TWT Wu
T Wu
HJH Ji
H Ji
FYFenghong Yuan
Fenghong Yuan
To investigate the function of mitophagy in instructing T-cell differentiation of patients with rheumatoid arthritis (RA). The mRNA and protein levels of optic atrophy protein-1 were detected in T cells from 94 RA patients and 37 age- and sex-matched healthy individuals by quantitative polymerase chain reaction and Western blotting. The impact of mitophagy on the differentiation of T cells was determined by flow cytometry. The therapeutic effect of targeting mitophagy was explored in humanized RA chimeras. Our study showed that T cells exerted high levels of mitophagy in RA patients. Since multiple T-cell subtypes play crucial roles in RA, we determined that mitophagy had a significant impact on the differentiation of tissue-resident memory T (Trm) cells, but not Th1 or Th17 cells. Importantly, we demonstrated that inhibiting mitophagy significantly reduced the number of Trm cells and downregulated inflammatory responses, as evidenced by diminished levels of T cell receptor β, interferon-γ, and interleukin-17A, in the humanized RA chimeras. Mitophagy is elevated in RA T cells, leading to maldifferentiation of Trm cells in RA patients. Since these findings were obtained from clinical patients, mitophagy may be a potential therapeutic target for RA treatment.

1 August 2023 in Aging Cell
Verified
Journal Article
Open access
NYNa Yuan
Na Yuan
WWWen Wei
Wen Wei
JLJI LI
JI LI
JQJiawei Qian
Jiawei Qian
ZJZhicong Jin
Zhicong Jin
JWJianrong Wang
Jianrong Wang


24 October 2025 in Medicine
Verified
Journal Article
Open access
YWYihan Wang
Yihan Wang
ZLZhen Liu
Zhen Liu
SDShengbao Duan
Shengbao Duan
CLChunyan Lin
Chunyan Lin
YJYiming Jin
Yiming Jin
MWMingyuan Wang
Mingyuan Wang
Rationale: Platelet transfusions are the key treatment for patients with severely low platelet counts and significant bleeding symptoms. Platelet transfusion refractorines (PTR) is defined as unsatisfactory transfusion of platelets with at least 2 ABO blood groups matched and stored for <72 hours. Patient concerns: A 37-year-old woman presented for medical evaluation due to the cessation of fetal heart activity after 50 days of gestation. Diagnoses: AML-M2, PTR. Interventions: To explore potential immune-mediated causes of platelet refractoriness, the following diagnostic evaluations were conducted: Platelet antibody screening using the PAK-Lx assay (Immucor) to detect anti-HLA class I and HPA antibodies. Anti-HLA class I specificity determination via LIFECODES LSA Single Antigen bead assays (Luminex). Molecular typing of HLA class I and HPA alleles using PCR-sequence based typing (PCR-SBT), as well as CD36 phenotyping via flow cytometry. Confirmation testing for anti-HPA-5b antibodies using chloroquine-treated platelet solid-phase assays. Outcomes: The patient had high-fluorescence-intensity HLA antibodies along with HPA antibodies, resulting in severe refractoriness to platelet transfusion. Lessons: Various methods were used to comprehensively analyze the specificity of anti-platelet antibodies in the samples of patients with ineffective platelet transfusion, thus providing a reference for the clinical diagnosis and treatment of PTR.